A TRIM21-based bioPROTAC highlights the therapeutic benefit of HuR degradation

Alice Fletcher(AstraZeneca (United Kingdom)), James Hunt(AstraZeneca (United Kingdom))
Nature Communications
November 4, 2023
10.1038/s41467-023-42546-2
Cited by 41

Related Papers

No related papers found

Powered by citation graph analysis